Home > Publications Database > Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. > print

001     155926
005     20240918142432.0
024 7 _ |a 10.1016/j.neuropharm.2020.108081
|2 doi
024 7 _ |a pmid:32407924
|2 pmid
024 7 _ |a 0028-3908
|2 ISSN
024 7 _ |a 1873-7064
|2 ISSN
024 7 _ |a altmetric:82089504
|2 altmetric
037 _ _ |a DZNE-2021-01080
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Vergallo, Andrea
|b 0
245 _ _ |a Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery.
260 _ _ |a Amsterdam [u.a.]
|c 2021
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726662245_30554
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a When Alzheimer's disease (AD) disease-modifying therapies will be available, global healthcare systems will be challenged by a large-scale demand for clinical and biological screening. Validation and qualification of globally accessible, minimally-invasive, and time-, cost-saving blood-based biomarkers need to be advanced. Novel pathophysiological mechanisms (and related candidate biomarkers) - including neuroinflammation pathways (TREM2 and YKL-40), axonal degeneration (neurofilament light chain protein), synaptic dysfunction (neurogranin, synaptotagmin, α-synuclein, and SNAP-25) - may be integrated into an expanding pathophysiological and biomarker matrix and, ultimately, integrated into a comprehensive blood-based liquid biopsy, aligned with the evolving ATN + classification system and the precision medicine paradigm. Liquid biopsy-based diagnostic and therapeutic algorithms are increasingly employed in Oncology disease-modifying therapies and medical practice, showing an enormous potential for AD and other brain diseases as well. For AD and other neurodegenerative diseases, newly identified aberrant molecular pathways have been identified as suitable therapeutic targets and are currently investigated by academia/industry-led R&D programs, including the nerve-growth factor pathway in basal forebrain cholinergic neurons, the sigma1 receptor, and the GTPases of the Rho family. Evidence for a clinical long-term effect on cognitive function and brain health span of cholinergic compounds, drug candidates for repositioning programs, and non-pharmacological multidomain interventions (nutrition, cognitive training, and physical activity) is developing as well. Ultimately, novel pharmacological paradigms, such as quantitative systems pharmacology-based integrative/explorative approaches, are gaining momentum to optimize drug discovery and accomplish effective pathway-based strategies for precision medicine. This article is part of the special issue on 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer's disease
|2 Other
650 _ 7 |a Blood biomarkers
|2 Other
650 _ 7 |a Disease-modifying therapies
|2 Other
650 _ 7 |a Liquid biopsy
|2 Other
650 _ 7 |a Precision medicine
|2 Other
650 _ 7 |a Systems pharmacology
|2 Other
650 _ 2 |a Alzheimer Disease: diagnosis
|2 MeSH
650 _ 2 |a Alzheimer Disease: drug therapy
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Anti-Inflammatory Agents: administration & dosage
|2 MeSH
650 _ 2 |a Anti-Inflammatory Agents: metabolism
|2 MeSH
650 _ 2 |a Drug Discovery: methods
|2 MeSH
650 _ 2 |a Drug Discovery: trends
|2 MeSH
650 _ 2 |a Drug Repositioning: methods
|2 MeSH
650 _ 2 |a Drug Repositioning: trends
|2 MeSH
650 _ 2 |a Forecasting
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Intracellular Fluid: drug effects
|2 MeSH
650 _ 2 |a Intracellular Fluid: metabolism
|2 MeSH
650 _ 2 |a Liquid Biopsy: methods
|2 MeSH
650 _ 2 |a Liquid Biopsy: trends
|2 MeSH
650 _ 2 |a Membrane Glycoproteins: metabolism
|2 MeSH
650 _ 2 |a Pharmacology, Clinical: methods
|2 MeSH
650 _ 2 |a Pharmacology, Clinical: trends
|2 MeSH
650 _ 2 |a Receptors, Immunologic: metabolism
|2 MeSH
650 _ 2 |a Signal Transduction: drug effects
|2 MeSH
650 _ 2 |a Signal Transduction: physiology
|2 MeSH
650 _ 2 |a Systems Biology: methods
|2 MeSH
650 _ 2 |a Systems Biology: trends
|2 MeSH
700 1 _ |a Caraci, Filippo
|b 1
700 1 _ |a Cuello, A Claudio
|b 2
700 1 _ |a Lemercier, Pablo
|b 3
700 1 _ |a Vellas, Bruno
|b 4
700 1 _ |a Giudici, Kelly Virecoulon
|b 5
700 1 _ |a Hampel, Harald
|b 6
700 1 _ |a Baldacci, Filippo
|b 7
700 1 _ |a Hänisch, Britta
|0 P:(DE-2719)2810511
|b 8
700 1 _ |a Haberkamp, Marion
|b 9
700 1 _ |a Broich, Karl
|b 10
700 1 _ |a Nisticò, Robert
|b 11
700 1 _ |a Emanuele, Enzo
|b 12
700 1 _ |a Llavero, Francisco
|b 13
700 1 _ |a Zugaza, José L
|b 14
700 1 _ |a Lucía, Alejandro
|b 15
700 1 _ |a Giacobini, Ezio
|b 16
700 1 _ |a Lista, Simone
|0 P:(DE-2719)2810761
|b 17
700 1 _ |a Initiative, Alzheimer Precision Medicine
|b 18
|e Collaboration Author
773 _ _ |a 10.1016/j.neuropharm.2020.108081
|g Vol. 185, p. 108081 -
|0 PERI:(DE-600)1500655-4
|p 108081
|t Neuropharmacology
|v 185
|y 2021
|x 0028-3908
856 4 _ |u https://pub.dzne.de/record/155926/files/DZNE-2021-01080_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/155926/files/DZNE-2021-01080_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:155926
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810511
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 17
|6 P:(DE-2719)2810761
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-30
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-30
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-30
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-24
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-24
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROPHARMACOLOGY : 2021
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-24
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEUROPHARMACOLOGY : 2021
|d 2022-11-24
920 1 _ |0 I:(DE-2719)1013010
|k AG Hänisch
|l Pharmacoepidemiology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1013010
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21